Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Ongoing research and investigational therapies, such as GIP/GLP-1/glucagon triple agonists, may inform future strategies for sustainable weight loss after discontinuation of weight loss pharmacotherapy
Certain medications may interfere with tirzepatide's effectivenessparticularly drugs that affect gastric motility or glucose metabolism
This receptor specificity makes it a reference reagent for investigating clean GH-axis activation and downstream effects on body composition, bone density, and metabolic homeostasis
Lifestyle interventions (including diet, exercise and behavioural changes) are the cornerstone of obesity management with diverse benefits, but even the most intensive lifestyle interventions result in up to 10% mean weight loss (WL) and weight maintenance remains a challenge, as 80% of WL is expected to be regained over the next 5 years [4, 5]
